Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance

Abstract excerpt

Tamoxifen is a first-line endocrine agent in the mechanism-based treatment of estrogen receptor positive (ER(+)) mammary carcinoma and applied to breast cancer patients all over the world. Endoxifen is a secondary and highly active metabolite of tamoxifen that is formed among others by the polymorphic cytochrome P450 2D6 (CYP2D6). It is widely accepted that CYP2D6 poor metabolizers exert a pronounced decrease in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Estrogen and related hormone effects
• Share to Inflammatory mediators and NSAID effects
• Share to Pharmacogenetics and Drug Metabolism